Wealth Enhancement Advisory Services LLC Purchases 11,648 Shares of Sanofi $SNY

Wealth Enhancement Advisory Services LLC increased its position in Sanofi (NASDAQ:SNY) by 16.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 82,623 shares of the company’s stock after purchasing an additional 11,648 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Sanofi were worth $3,980,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Financial Consulate Inc. purchased a new stake in Sanofi during the 3rd quarter valued at $26,000. Measured Wealth Private Client Group LLC bought a new stake in Sanofi in the 3rd quarter worth $29,000. Palisade Asset Management LLC purchased a new position in shares of Sanofi in the third quarter valued at about $30,000. First Horizon Corp bought a new position in shares of Sanofi during the third quarter valued at about $33,000. Finally, Salomon & Ludwin LLC raised its stake in shares of Sanofi by 1,046.3% during the third quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after acquiring an additional 701 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Trading Down 0.1%

NASDAQ:SNY opened at $46.72 on Tuesday. The company has a 50-day moving average price of $46.32 and a 200-day moving average price of $47.99. The stock has a market cap of $113.95 billion, a price-to-earnings ratio of 12.98, a P/E/G ratio of 1.16 and a beta of 0.45. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. Sanofi has a 12 month low of $43.32 and a 12 month high of $55.77.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SNY. Barclays cut Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. Guggenheim lowered Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. TD Cowen reiterated a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Hold” and a consensus target price of $61.50.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.